2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-169043
    (±)7(S),8(R)-EDT 355016-21-6 98%
    (±)7(S),8(R)-EDT is an isomer of 7,8-EDT.
    (±)7(S),8(R)-EDT
  • HY-169044
    (±)10,11-EDT 355016-20-5 98%
    (±)10,11-EDT is an oxylipin and a metabolite of Adrenic acid (HY-W013215).
    (±)10,11-EDT
  • HY-169046
    (±)13,14-DiHDoTrE 944908-94-5 98%
    (±)13,14-DiHDoTrE ((±)13,14-DHDT) is an oxylipin and a metabolite of Adrenic acid (HY-W013215).
    (±)13,14-DiHDoTrE
  • HY-169066
    INSR agonist 1 98%
    INSR agonist 1 is an insulin receptor (INSR) agonist. INSR agonist 1 can increase INSR pY1355/1361 levels and works synergistically with insulin.
    INSR agonist 1
  • HY-169110
    DPP-4-IN-12 98%
    DPP-4-IN-12 (compound 46) is a potent DPP-4 inhibitor with IC50 value of 2 nM. DPP-4-IN-12 can be used in the study of type 2 diabetes.
    DPP-4-IN-12
  • HY-169117
    α-Glucosidase-IN-74 98%
    α-Glucosidase-IN-74 (Compound 7d), an isatin-thiazole derivative, is a α-glucosidase inhibitor. α-Glucosidase-IN-74 exhibits antidiabetic activity by decreasing glycaemia and triglyceride levels in Streptozotocin (HY-13753)-induced diabetic animals.
    α-Glucosidase-IN-74
  • HY-169139
    Spiroglumide 137795-35-8 98%
    Spiroglumide (CR-2194) is a selective cholecystokinin B (CCKB) receptor antagonist.
    Spiroglumide
  • HY-169159
    SIRT6 activator 2 2867630-96-2 98%
    SIRT6 activator 2 (compound 31) is a sirtuin 6 activator with anti-lipid accumulation properties. SIRT6 activator 2 significantly downregulates LXR, SREBP-1c, and their target genes associated with lipogenesis, and can be used for research related to lipid metabolism-related diseases.
    SIRT6 activator 2
  • HY-169249
    Aekatperone 98%
    Aekatperone is a reversible KATP channel inhibitor, with an IC50 of 9 μM. Aekatperone can be used for the research of congenital hyperinsulinism (CHI).
    Aekatperone
  • HY-169251
    α-Glucosidase-IN-75 98%
    α-Glucosidase-IN-75 (compound 13) is an α-glucosidase inhibitor with an IC50 of 3.81 μM. α-Glucosidase-IN-75 can be used for the study of high glucose-induced cardiovascular diseases.
    α-Glucosidase-IN-75
  • HY-169254
    sPLA2 inhibitor 2 98%
    sPLA2 inhibitor 2 (compound 6a) is a sPLA2 inhibitor, with IC50 of 0.0475 μM. sPLA2 inhibitor 2 can be used in diabetes research.
    sPLA2 inhibitor 2
  • HY-169255
    sPLA2 inhibitor 3 98%
    sPLA2 inhibitor 3 (Compound 6c) is a potent α-glucosidase inhibitor (IC50 = 0.0953 µM). sPLA2 inhibitor 3 can be used for the research of diabetes.
    sPLA2 inhibitor 3
  • HY-169258
    PDE4-IN-21 98%
    PDE4-IN-21 (Compound L19) is a poetent PDE4 inhibitor, with an IC50 of 0.48 μM. PDE4-IN-21 exhibits good inhibitory activity and remarkable metabolic stability in rat liver microsomes.
    PDE4-IN-21
  • HY-169267
    BRD-K44839765 303066-86-6 98%
    BRD-K44839765 is selective against Bcl-2 with an IC50 value of 5.6 μM in IMR-90 cell. BRD-K44839765 has oral activity.
    BRD-K44839765
  • HY-169283
    α-Glycosidase-IN-2 98%
    α-Glycosidase-IN-2 (compound 8b) is a α-Glycosidase inhibitor with the Ki values of 74.16 nM and 6.09 nM for aldose reductase and α-glycosidase,respectively. α-Glycosidase-IN-2 can be used for study of diabetes mellitus.
    α-Glycosidase-IN-2
  • HY-169328
    Tyrosinase-IN-39 98%
    Tyrosinase-IN-39 (compound 5r) is a competitive tyrosinase inhibitor with the IC50 of 6.4 μM and can be used for study of skin diseases.
    Tyrosinase-IN-39
  • HY-169334
    BDK-IN-1 98%
    BDK-IN-1 (compound (-)-43) is a BDK inhibitor with the IC50 of 0.23 μM and the max inhibition of 90%. BDK-IN-1 decreases the level of phospho-E1 and can be used for study of cardiometabolic diseases.
    BDK-IN-1
  • HY-16938R
    5'-Methylthioadenosine (Standard) 2457-80-9 98%
    5'-Methylthioadenosine (Standard) is the analytical standard of 5'-Methylthioadenosine. This product is intended for research and analytical applications. 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis[1]. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis[2].
    5'-Methylthioadenosine (Standard)
  • HY-169404
    PPARγ agonist 15 98%
    PPARγ agonist 15 (Compound 7c) is an agonist for PPARγ. PPARγ agonist 15 inhibits the expression of alpha-amylase (HPA) and alpha-glucosidase (HLAG) with IC50 of 28.35 µM and 26.21 µM. PPARγ agonist 15 enhances glucose uptake in the L6 myotube cell. PPARγ agonist 15 improves glucose homeostasis, insulin sensitivity, and lipid metabolism in rat Streptozotocin (HY-13753)-induced diabetes model.
    PPARγ agonist 15
  • HY-169411
    α-Glucosidase-IN-77 98%
    α-Glucosidase-IN-77 (Compound H7) is a non-competitive inhibitor for α-glucosidase with an IC50 of 1.25 μM. α-Glucosidase-IN-77 lowers blood glucose levels, improves glucose tolerance, regulates intestinal microbiota, and exhibits hepatoprotective effect in mouse type 2 diabetes model.
    α-Glucosidase-IN-77
Cat. No. Product Name / Synonyms Application Reactivity